Health-related quality of life in Japanese patients with multiple sclerosis.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 18 08 2022
accepted: 25 10 2022
revised: 24 10 2022
pubmed: 6 11 2022
medline: 2 2 2023
entrez: 5 11 2022
Statut: ppublish

Résumé

Neurological disabilities, especially physical issues, can adversely affect the daily lives of people with multiple sclerosis (MS) and negatively impact their health-related quality of life (HRQOL). On the other hand, physical and psychiatric symptoms are variable in people with MS, and QOL can be influenced by cultural and educational background. This study aimed to evaluate the association of HRQOL with disabilities, fatigue, and depression in Japanese subjects with MS. Evaluation of HRQOL, fatigue, and depression was performed in 184 Japanese individuals with MS, using the Functional Assessment of MS (FAMS), Fatigue Severity Scale (FSS), and Beck Depression Inventory-Second Edition (BDI-II), respectively. Multiple linear regression analysis demonstrated negative correlations of the Expanded Disability Status Scale (EDSS) with scores on the FAMS subscales of mobility, symptoms, thinking and fatigue, total FAMS, and additional concerns. The FSS score had negative correlations with mobility, symptoms, emotional well-being, thinking and fatigue, total FAMS, and additional concerns. There were negative correlations between BDI-II scores and all items of FAMS. HRQOL had relatively close correlations with disabilities and fatigue, and depression had an especially close relationship with HRQOL.

Identifiants

pubmed: 36334134
doi: 10.1007/s00415-022-11453-9
pii: 10.1007/s00415-022-11453-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1011-1018

Subventions

Organisme : Ministry of Health, Labor, and Welfare of Japan
ID : 20FC1030

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Références

Oliva Ramirez A, Keenan A, Kalau O et al (2021) Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review. BMC Neurol 21:468. https://doi.org/10.1186/s12883-021-02396-1
doi: 10.1186/s12883-021-02396-1
Benito-León J, Morales JM, Rivera-Navarro J et al (2003) A review about the impact of multiple sclerosis on health-related quality of life. Disabil Rehabil 25:1291–1303. https://doi.org/10.1080/09638280310001608591
doi: 10.1080/09638280310001608591
Gil-González I, Martín-Rodríguez A, Conrad R et al (2020) Quality of life in adults with multiple sclerosis: a systematic review. BMJ Open 10:e041249. https://doi.org/10.1136/bmjopen-2020-041249
doi: 10.1136/bmjopen-2020-041249
Riemsma RP, Forbes CA, Glanville JM et al (2001) General health status measures for people with cognitive impairment: learning disability and acquired brain injury. Health Technol Assess 5:1–100. https://doi.org/10.3310/hta5060
doi: 10.3310/hta5060
Wiebe S, Guyatt G, Weaver B et al (2003) Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol 56:52–60. https://doi.org/10.1016/s0895-4356(02)00537-1
doi: 10.1016/s0895-4356(02)00537-1
Cella DF, Dineen K, Arnason B et al (1996) Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 47:129–139. https://doi.org/10.1212/wnl.47.1.129
doi: 10.1212/wnl.47.1.129
Kikuchi H, Mifune N, Niino M et al (2011) Impact and characteristics of quality of life in Japanese patients with multiple sclerosis. Qual Life Res 20:119–131. https://doi.org/10.1007/s11136-010-9725-2
doi: 10.1007/s11136-010-9725-2
Multiple Sclerosis Clinical Practice Guidelines (1998) Fatigue and multiple sclerosis: evidence-based management strategies for fatigue in multiple sclerosis. Paralyzed Veterans of America, Washington
Schmidt S, Jöstingmeyer P (2019) Depression, fatigue and disability are independently associated with quality of life in patients with multiple Sclerosis: results of a cross-sectional study. Mult Scler Relat Disord 35:262–269. https://doi.org/10.1016/j.msard.2019.07.029
doi: 10.1016/j.msard.2019.07.029
Kagawa-Singer M, Padilla GV, Ashing-Giwa K (2010) Health-related quality of life and culture. Semin Oncol Nurs 26:59–67. https://doi.org/10.1016/j.soncn.2009.11.008
doi: 10.1016/j.soncn.2009.11.008
Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173. https://doi.org/10.1016/S1474-4422(17)30470-2
doi: 10.1016/S1474-4422(17)30470-2
Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177–189. https://doi.org/10.1212/WNL.0000000000001729
doi: 10.1212/WNL.0000000000001729
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33:1444–1452. https://doi.org/10.1212/wnl.33.11.1444
doi: 10.1212/wnl.33.11.1444
Krupp LB, LaRocca NG, Muir-Nash J et al (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123. https://doi.org/10.1001/archneur.1989.00520460115022
doi: 10.1001/archneur.1989.00520460115022
Beck AT, Steer RA, Ball R et al (1996) Comparison of beck depression inventories -IA and -II in psychiatric outpatients. J Pers Assess 67:588–597. https://doi.org/10.1207/s15327752jpa6703_13
doi: 10.1207/s15327752jpa6703_13
Kojima M, Furukawa TA, Takahashi H et al (2002) Cross-cultural validation of the Beck Depression Inventory—II in Japan. Psychiatry Res 110:291–299. https://doi.org/10.1016/s0165-1781(02)00106-3
doi: 10.1016/s0165-1781(02)00106-3
Chang CH, Cella D, Fernández O et al (2002) Quality of life in multiple sclerosis patients in Spain. Mult Scler 8:527–531. https://doi.org/10.1191/1352458502ms851oa
doi: 10.1191/1352458502ms851oa
Pluta-Fuerst A, Petrovic K, Berger T et al (2011) Patient-reported quality of life in multiple sclerosis differs between cultures and countries: a cross-sectional Austrian-German-Polish study. Mult Scler 17:478–486. https://doi.org/10.1177/1352458510391341
doi: 10.1177/1352458510391341
Pashazadeh Kan F, Hoseinipalangi Z, Ahmadi N et al (2022) Global, regional and national quality of life in patients with multiple sclerosis: a global systematic review and meta-analysis. BMJ Support Palliat Care 12:158–166. https://doi.org/10.1136/bmjspcare-2020-002604
doi: 10.1136/bmjspcare-2020-002604
Houzen H, Kondo K, Horiuchi K et al (2018) Consistent increase in the prevalence and female ratio of multiple sclerosis over 15 years in northern Japan. Eur J Neurol 25:334–339. https://doi.org/10.1111/ene.13506
doi: 10.1111/ene.13506
Piccolo L, Kumar G, Nakashima I et al (2015) Multiple sclerosis in Japan appears to be a milder disease compared to the UK. J Neurol 262:831–836. https://doi.org/10.1007/s00415-015-7637-3
doi: 10.1007/s00415-015-7637-3
Acaster S, Swinburn P, Wang C et al (2011) Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. Mult Scle 17:1504–1513. https://doi.org/10.1177/1352458511414039
doi: 10.1177/1352458511414039
Sørensen J, Bay J, Damsgaard T et al (2011) Validation of the danish version of functional assessment of multiple sclerosis: a quality of life instrument. Mult Scler Int 2011:121530. https://doi.org/10.1155/2011/121530
doi: 10.1155/2011/121530
Vickrey BG, Hays RD, Harooni R et al (1995) A health-related quality of life measure for multiple sclerosis. Qual Life Res 4:187–206. https://doi.org/10.1007/BF02260859
doi: 10.1007/BF02260859
Hemmett L, Holmes J, Barnes M et al (2004) What drives quality of life in multiple sclerosis? QJM 97:671–676. https://doi.org/10.1093/qjmed/hch105
doi: 10.1093/qjmed/hch105
Garg H, Bush S, Gappmaier E (2016) Associations Between Fatigue and Disability, Functional Mobility, Depression, and Quality of Life in People with Multiple Sclerosis. Int J MS Care 18:71–77. https://doi.org/10.7224/1537-2073.2015-013
doi: 10.7224/1537-2073.2015-013
Fernández-Muñoz JJ, Morón-Verdasco A, Cigarán-Méndez M et al (2015) Disability, quality of life, personality, cognitive and psychological variables associated with fatigue in patients with multiple sclerosis. Acta Neurol Scand 132:118–124. https://doi.org/10.1111/ane.12370
doi: 10.1111/ane.12370
Young CA, Mills R, Rog D et al (2021) Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy. J Neurol Sci 426:117437. https://doi.org/10.1016/j.jns.2021.117437
doi: 10.1016/j.jns.2021.117437
Oreja-Guevara C, Ayuso Blanco T, Brieva Ruiz L et al (2019) Cognitive dysfunctions and assessments in multiple sclerosis. Front Neurol 10:581. https://doi.org/10.3389/fneur.2019.00581
doi: 10.3389/fneur.2019.00581
Reese JP, Wienemann G, John A et al (2013) Preference-based Health status in a German outpatient cohort with multiple sclerosis. Health Qual Life Outcomes 11:162. https://doi.org/10.1186/1477-7525-11-162
doi: 10.1186/1477-7525-11-162
Yalachkov Y, Soydaş D, Bergmann J et al (2019) Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis. Mult Scler Relat Disord 30:33–37. https://doi.org/10.1016/j.msard.2019.01.049
doi: 10.1016/j.msard.2019.01.049
Merkelbach S, Sittinger H, Koenig J (2002) Is there a differential impact of fatigue and physical disability on quality of life in multiple sclerosis? J Nerv Ment Dis 190:388–393. https://doi.org/10.1097/00005053-200206000-00007
doi: 10.1097/00005053-200206000-00007
Ochoa-Morales A, Hernández-Mojica T, Paz-Rodríguez F et al (2019) Quality of life in patients with multiple sclerosis and its association with depressive symptoms and physical disability. Mult Scler Relat Disord 36:101386. https://doi.org/10.1016/j.msard.2019.101386
doi: 10.1016/j.msard.2019.101386

Auteurs

Masaaki Niino (M)

Department of Clinical Research, National Hospital Organization Hokkaido Medical Center, Yamanote 5-Jo 7-Chome, Nishi-Ku, Sapporo, 063-0005, Japan. niino.masaaki.tc@mail.hosp.go.jp.

Shoko Fukumoto (S)

Department of Neurology, Graduate School of Medical Sciences, Neurological Institute, Kyushu University, Fukuoka, Japan.

Tatsusada Okuno (T)

Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan.

Nobuo Sanjo (N)

Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Tokyo, Japan.

Hikoaki Fukaura (H)

Department of Neurology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.

Masahiro Mori (M)

Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Takashi Ohashi (T)

Department of Neurology, Tokyo Women's Medical University Yachiyo Medical Center, Chiba, Japan.

Hideyuki Takeuchi (H)

Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Yuko Shimizu (Y)

Department of Neurology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.

Juichi Fujimori (J)

Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.

Izumi Kawachi (I)

Department of Neurology, Brain Research Institute, Niigata University Medical Education Center, Niigata University School of Medicine, Niigata, Japan.

Jun-Ichi Kira (JI)

Department of Neurology, Graduate School of Medical Sciences, Neurological Institute, Kyushu University, Fukuoka, Japan.

Eri Takahashi (E)

Department of Clinical Research, National Hospital Organization Hokkaido Medical Center, Yamanote 5-Jo 7-Chome, Nishi-Ku, Sapporo, 063-0005, Japan.

Yusei Miyazaki (Y)

Department of Clinical Research, National Hospital Organization Hokkaido Medical Center, Yamanote 5-Jo 7-Chome, Nishi-Ku, Sapporo, 063-0005, Japan.

Nobuhiro Mifune (N)

School of Economics and Management, Kochi University of Technology, Kochi, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH